Now available BIZENGRI®

BIZENGRI® is a bispecific HER2- and HER3-directed antibody indicated for the treatment of:

• Adults with advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) harboring aneuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.*
• Adults with advanced, unresectable, or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.*

*This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication
may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Please see full prescribing information here.